Healthcare, Pharma & Life Sciences

Cellular Intelligence Adds LeCun, Moderna's Langer to Advisory Board

Image
Cellular Intelligence Adds LeCun, Moderna's Langer to Advisory Board

Boston – September 21, 2026 -- Cellular Intelligence, a Boston-based AI company building a universal foundation model of cell signaling, has appointed Turing Award laureate Yann LeCun, Moderna co-founder Robert "Bob" Langer, BioInnovation Institute CEO Jens Nielsen and Helmholtz Munich computational health director Fabian Theis to its Scientific Advisory Board. Langer also joins the company's Board of Directors as an observer.

Telix to Acquire ITM in $1.65B Deal, Forming Radiopharma Giant

Image
Telix to Acquire ITM in $1.65B Deal, Forming Radiopharma Giant

Melbourne – September 21, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has signed a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valuing ITM at US$1.65 billion upfront on a cash-free, debt-free basis, with up to US$700 million in additional contingent consideration tied to regulatory and sales milestones.

Deal structures $1.25 billion in Telix stock alongside debt assumption

Under the agreement, ITM shareholders will receive approximately US$1.25 billion in the form of 105.8 million Telix shares priced at US$11.84 per share, released as Nasdaq-listed ADRs following escrow periods of up to 15 months. Telix will additionally assume US$302 million of ITM net debt at closing, with US$96 million allocated to management equity rollover and transaction expenses. Upon completion, existing Telix shareholders will hold roughly 76.3% of the combined company, with ITM shareholders holding approximately 23.7%.

Abbisko's Lavengratinib Shows 2.4cm/Year Growth Gain in Achondroplasia Trial

Image
Abbisko's Lavengratinib Shows 2.4cm/Year Growth Gain in Achondroplasia Trial

Shanghai – September 21, 2026 -- Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK) reported that its oral FGFR2/3 inhibitor lavengratinib achieved a mean increase of 2.4 cm/year in annualized height velocity among children with achondroplasia in the lowest-dose cohort of a Phase II trial, with a 100% responder rate.

Seven children in the first dose cohort completed six months of treatment with no serious adverse events

All seven participants aged 6 to 12 in cohort 1 of the ABSK061-202 study received lavengratinib at 0.064 mg/kg once daily for 27 weeks. Responders were defined as achieving at least a 25% improvement in annualized height velocity from baseline, a threshold every participant in the cohort met.

Antengene Doses First Patient in Phase III Trial of ADC ATG-022

Image
Antengene Doses First Patient in Phase III Trial of ADC ATG-022

Shanghai – September 21, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has dosed the first patient in China in its pivotal Phase III CLINCH-3 study evaluating ATG-022, a CLDN18.2 antibody-drug conjugate, as monotherapy for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Breakthrough Therapy Designation accelerated the trial's launch

China's National Medical Products Administration granted ATG-022 Breakthrough Therapy Designation, which the company says streamlined regulatory communications and enabled the rapid start of CLINCH-3. The randomized, controlled, open-label multicenter study is initiated in China and planned for expansion into a multi-regional clinical trial, with Professor Lin Shen of Peking University Cancer Hospital serving as principal investigator. The study compares ATG-022 against treatment of investigator's choice, targeting a future marketing approval application.

Specialised Therapeutics Expands Incyte Deal for Opzelura in Australia

Image
Specialised Therapeutics Expands Incyte Deal for Opzelura in Australia

Singapore – September 21, 2026 -- Specialised Therapeutics (ST) has expanded its partnership with Incyte Biosciences International to commercialise, distribute, and register ruxolitinib cream, marketed as Opzelura, in Australia.

ST gains rights to market Opzelura for vitiligo and atopic dermatitis in Australia

Under the expanded agreement, Incyte will continue to develop and manufacture ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, while ST takes on regulatory submissions, medical affairs, marketing, and distribution across the Australian market. The drug is approved in the U.S. and European Union for treating non-segmental vitiligo and mild-to-moderate atopic dermatitis in patients who do not respond adequately to standard topical therapies.

Field Medical's PFA Catheter Hits 94.2% Vein Durability in 12-Month Trial

Image
Field Medical's PFA Catheter Hits 94.2% Vein Durability in 12-Month Trial

Atlanta and Carlsbad, Calif. – September 21, 2026 -- Field Medical, Inc. reported 12-month outcomes from its first-in-human Field PULSE trial showing 94.2% per-vein durability for pulmonary vein isolation using an optimized waveform, with results published in JACC: Clinical Electrophysiology and presented as a Late-Breaking Clinical Trial at HRX Live 2026.

Subsecond ablation cuts median procedure time to 13 minutes

The trial recorded a 13-minute median elapsed pulmonary vein isolation (PVI) ablation time, with a fastest case completed in 7.7 minutes. Field Medical's high-voltage focal pulsed field ablation (PFA) architecture, delivered through its FieldForce PFA System, applies energy in under 200 milliseconds per point, reducing the need for prolonged catheter stability during atrial procedures.

Wearable Nerve Stimulator Shows Signal in Reducing AF Recurrence Post-Ablation

Image
Wearable Nerve Stimulator Shows Signal in Reducing AF Recurrence Post-Ablation

Atlanta and Los Angeles – September 21, 2026 -- StimCardio Medical reported that patients treated with non-invasive median nerve stimulation (MNS) after atrial fibrillation (AF) ablation showed 90.0% freedom from atrial arrhythmias at six months, compared with 80.8% for those receiving sham treatment, though the difference did not reach statistical significance. The randomized, double-blind, sham-controlled NeuroPulse pilot study was presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in the peer-reviewed journal Heart Rhythm.

Post-blanking analysis finds statistically significant drop in arrhythmia events

In a sensitivity analysis conducted after the 60-day blanking period, patients receiving MNS recorded 12 recurrent atrial arrhythmia events versus 28 in the sham group, a statistically significant reduction (p=0.025). No MNS- or device-related serious adverse events were reported across the trial.

S2S China Names 10 Biotech Finalists for Westlake Pitch Event

Image
S2S China Names 10 Biotech Finalists for Westlake Pitch Event

Shanghai – – September 21, 2026 -- Ten biotech startup teams have been selected as finalists for the inaugural S2S China Symposium, narrowed from roughly 20 semifinalists who competed to pitch global venture investors at Westlake University on October 15.

RA Capital and Qiming Venture Partners co-host China chapter of Science2Startup

S2S China is the China chapter of Science2Startup, an invitation-only program founded in 2018 by F-Prime, SV Health and Atlas Venture that connects academic therapeutics researchers with biotech investors. RA Capital Management, Osage University Partners and 5AM Ventures have since joined the network. The China edition is co-hosted by RA Capital Management and Qiming Venture Partners.

Accro Bioscience Doses First Patient in AC-101 Phase IIb UC Trial

New York and Suzhou, China – September 21, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).

Trial spans roughly 50 clinical sites with three treatment arms

The multicenter, double-blind, placebo-controlled study is designed across approximately 50 clinical sites and includes two AC-101 dose cohorts plus a placebo control arm. The primary endpoint is clinical remission rate at Week 12, with exploratory endpoints covering histologic remission and long-term maintenance of clinical and histologic remission.

Par Health Recalls Two Dexmedetomidine Lots Over Particulate Risk

Image
Par Health Recalls Two Dexmedetomidine Lots Over Particulate Risk

Rochester, Mich. – September 21, 2026 -- Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) at the hospital level after detecting particulate matter identified as cellulose or stopper material.

Contaminated vials carry risk of pulmonary emboli and vessel occlusion

The FDA-notified recall covers Lots 87558 and 88802, which were distributed nationwide to wholesalers between September 21, 2026 and September 21, 2026. Par Health warned that administering the affected product carries a reasonable probability of causing life-threatening adverse health consequences, including pulmonary emboli, occlusions of other blood vessels that can lead to tissue death and organ damage, and inflammation of vein walls that may result in clotting. The company said it has not received any adverse event reports tied to the recall to date.